SG11202007606QA - Compositions and methods for membrane protein delivery - Google Patents
Compositions and methods for membrane protein deliveryInfo
- Publication number
- SG11202007606QA SG11202007606QA SG11202007606QA SG11202007606QA SG11202007606QA SG 11202007606Q A SG11202007606Q A SG 11202007606QA SG 11202007606Q A SG11202007606Q A SG 11202007606QA SG 11202007606Q A SG11202007606Q A SG 11202007606QA SG 11202007606Q A SG11202007606Q A SG 11202007606QA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- membrane protein
- protein delivery
- delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862631747P | 2018-02-17 | 2018-02-17 | |
PCT/US2019/018324 WO2019161281A1 (en) | 2018-02-17 | 2019-02-15 | Compositions and methods for membrane protein delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202007606QA true SG11202007606QA (en) | 2020-09-29 |
Family
ID=65767294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202007606QA SG11202007606QA (en) | 2018-02-17 | 2019-02-15 | Compositions and methods for membrane protein delivery |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210137839A1 (en) |
EP (1) | EP3752623A1 (en) |
JP (1) | JP2021513849A (en) |
KR (1) | KR20200144093A (en) |
CN (1) | CN112272706A (en) |
AU (1) | AU2019222560A1 (en) |
BR (1) | BR112020016570A2 (en) |
CA (1) | CA3091478A1 (en) |
IL (1) | IL276715A (en) |
MX (1) | MX2020008542A (en) |
SG (1) | SG11202007606QA (en) |
WO (1) | WO2019161281A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
KR20210131991A (en) * | 2018-11-14 | 2021-11-03 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | Compositions and methods for compartment-specific cargo delivery |
WO2021041473A1 (en) * | 2019-08-27 | 2021-03-04 | The Trustees Of Columbia University In The City Of New York | Engineered exosomes for targeted delivery |
US20220333132A1 (en) | 2019-09-03 | 2022-10-20 | Sana Blotechnology, Inc. | Cd24-associated particles and related methods and uses thereof |
WO2021237297A1 (en) * | 2020-05-27 | 2021-12-02 | Exopharm Limited | Anti-viral extracellular vesicles, their methods of preparation and uses |
AU2022227018A1 (en) * | 2021-02-26 | 2023-10-05 | Cytonus Therapeutics, Inc. | Compositions and methods for therapeutic delivery |
KR20240028975A (en) | 2021-04-08 | 2024-03-05 | 사나 바이오테크놀로지, 인크. | CD8-specific antibody constructs and compositions thereof |
CN117642420A (en) | 2021-05-28 | 2024-03-01 | 萨那生物科技公司 | Lipid particles comprising truncated baboon endogenous retrovirus (BaEV) envelope glycoproteins and related methods and uses |
CA3222298A1 (en) * | 2021-06-13 | 2022-12-22 | Osnat BOHANA-KASHTAN | Compositions comprising spherical particles and uses of same |
CA3236365A1 (en) | 2021-11-02 | 2023-05-11 | University Of Rochester | Tcf7l2 mediated remyelination in the brain |
WO2023115039A2 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
TW202342757A (en) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | Modified paramyxoviridae attachment glycoproteins |
WO2023193003A2 (en) * | 2022-03-31 | 2023-10-05 | Sana Biotechnology, Inc. | Cd4-specific antibody constructs and compositions and uses thereof |
WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2589095A (en) | 1994-05-16 | 1995-12-05 | Washington University | Cell membrane fusion composition and method |
GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
AU9399498A (en) | 1997-09-18 | 1999-04-05 | Trustees Of The University Of Pennsylvania, The | Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery |
US20040028687A1 (en) | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
CA2479763A1 (en) | 2002-03-27 | 2003-10-09 | Baylor College Of Medicine | Potent oncolytic herpes simplex virus for cancer therapy |
BR0316402A (en) | 2002-11-21 | 2006-02-21 | Pevion Biotech Ltd | fusogenic vesicle, methods for preparing an encapsulating fusogenic vesicle, and for encapsulating at least one therapeutic or immunologically active substance in a fusogenic vesicle, use of a fusogenic vesicle, and, pharmaceutical formulation |
JP2007514445A (en) | 2003-12-17 | 2007-06-07 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | Delivery of DNA or RNA via gap junction from host cell to target cell, and cell-based delivery system for antisense or siRNA |
WO2006027202A1 (en) | 2004-09-06 | 2006-03-16 | Unite De Recherche En Biotherapie Et Oncologie (Rubio) | Generation of multiparent cell hybrids |
WO2007099387A1 (en) | 2006-03-03 | 2007-09-07 | Mymetics Corporation | Virosome-like vesicles comprising gp41-derived antigens |
US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
US9642817B2 (en) | 2009-08-27 | 2017-05-09 | Technion Research & Development Foundation Limited | Liposomal compositions and uses of same |
US8697439B2 (en) * | 2009-11-13 | 2014-04-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Direct protein delivery with engineered microvesicles |
JP5947311B2 (en) | 2010-12-09 | 2016-07-06 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Use of chimeric antigen receptor modified T cells for the treatment of cancer |
US10421960B2 (en) | 2011-09-16 | 2019-09-24 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
US20160289674A1 (en) | 2012-04-02 | 2016-10-06 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
CA2930339A1 (en) | 2012-11-13 | 2014-05-22 | Jan Lotvall | Delivery of therapeutic agent |
AU2014251388B2 (en) | 2013-04-12 | 2017-03-30 | Evox Therapeutics Limited | Therapeutic delivery vesicles |
EP3008192B1 (en) | 2013-06-11 | 2019-07-17 | Takara Bio USA, Inc. | Protein enriched microvesicles and methods of making and using the same |
GB201313249D0 (en) * | 2013-07-25 | 2013-09-11 | Isis Innovation | Method |
US10246505B2 (en) | 2013-11-25 | 2019-04-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control HIV infection |
WO2015110957A2 (en) * | 2014-01-21 | 2015-07-30 | De Beer Joel | Hybridosomes, compositions comprising the same, processes for their production and uses thereof |
ES2688035T3 (en) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Universal antigen receptor that expresses immune cells for addressing multiple multiple antigens, procedure for manufacturing it and using it for the treatment of cancer, infections and autoimmune diseases |
WO2016077639A2 (en) | 2014-11-12 | 2016-05-19 | VL27, Inc. | Nanovesicular therapies |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US10624849B2 (en) | 2015-09-28 | 2020-04-21 | Northwestern University | Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites |
WO2017058753A1 (en) | 2015-09-28 | 2017-04-06 | Trustees Of Dartmouth College | Chimeric antigen receptor, regulatory cells and methods of use |
US20180264038A1 (en) | 2015-09-28 | 2018-09-20 | Regents Of The University Of Minnesota | Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity |
US20170112773A1 (en) | 2015-10-23 | 2017-04-27 | Board Of Regents, The University Of Texas System | Plasma membrane vesicles comprising functional transmembrane proteins |
EP3430024A4 (en) | 2016-03-15 | 2019-11-13 | Codiak BioSciences, Inc. | Therapeutic membrane vesicles |
US10538786B2 (en) | 2016-04-13 | 2020-01-21 | Janssen Pharmaceuticals, Inc. | Recombinant arterivirus replicon systems and uses thereof |
US20180028600A1 (en) * | 2016-07-15 | 2018-02-01 | Korea Institute Of Science And Technology | Novel recombinant exosome and use thereof |
US11242376B2 (en) | 2016-08-02 | 2022-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
ES2875959T3 (en) | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Compositions and methods for T-cell receptor reprogramming using fusion proteins |
BR112019007433A2 (en) | 2016-10-17 | 2019-07-02 | Synthetic Genomics Inc | recombinant virus replicon systems and uses thereof |
CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
BR112019011661A2 (en) | 2016-12-05 | 2020-01-07 | Synthetic Genomics, Inc. | COMPOSITIONS AND METHODS FOR INCREASING GENE EXPRESSION |
AU2017382902A1 (en) | 2016-12-21 | 2019-07-18 | TCR2 Therapeutics Inc. | Engineered T cells for the treatment of cancer |
WO2018208728A1 (en) | 2017-05-08 | 2018-11-15 | Flagship Pioneering, Inc. | Compositions for facilitating membrane fusion and uses thereof |
WO2018232020A1 (en) | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
-
2019
- 2019-02-15 CA CA3091478A patent/CA3091478A1/en active Pending
- 2019-02-15 JP JP2020543570A patent/JP2021513849A/en active Pending
- 2019-02-15 AU AU2019222560A patent/AU2019222560A1/en active Pending
- 2019-02-15 EP EP19711190.9A patent/EP3752623A1/en active Pending
- 2019-02-15 MX MX2020008542A patent/MX2020008542A/en unknown
- 2019-02-15 CN CN201980026862.2A patent/CN112272706A/en active Pending
- 2019-02-15 WO PCT/US2019/018324 patent/WO2019161281A1/en active Application Filing
- 2019-02-15 BR BR112020016570-0A patent/BR112020016570A2/en unknown
- 2019-02-15 SG SG11202007606QA patent/SG11202007606QA/en unknown
- 2019-02-15 US US16/970,216 patent/US20210137839A1/en active Pending
- 2019-02-15 KR KR1020207026815A patent/KR20200144093A/en active Search and Examination
-
2020
- 2020-08-13 IL IL276715A patent/IL276715A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019161281A1 (en) | 2019-08-22 |
US20210137839A1 (en) | 2021-05-13 |
CA3091478A1 (en) | 2019-08-22 |
CN112272706A (en) | 2021-01-26 |
AU2019222560A1 (en) | 2020-08-27 |
EP3752623A1 (en) | 2020-12-23 |
JP2021513849A (en) | 2021-06-03 |
MX2020008542A (en) | 2021-01-08 |
BR112020016570A2 (en) | 2020-12-15 |
IL276715A (en) | 2020-09-30 |
KR20200144093A (en) | 2020-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276715A (en) | Compositions and methods for membrane protein delivery | |
IL276464A (en) | Methods and compositions for therapeutic protein delivery | |
IL273948A (en) | Compositions and methods for selective protein degradation | |
IL262321A (en) | Compositions and methods for selective protein expression | |
EP3866924A4 (en) | Compositions and methods for antibody delivery | |
EP3641762A4 (en) | N/o-linked degrons and degronimers for protein degradation | |
SG11202012004SA (en) | Rna-targeting fusion protein compositions and methods for use | |
EP3268050A4 (en) | Pore-forming protein conjugate compositions and methods | |
IL279505A (en) | Chimeric transmembrane proteins and uses thereof | |
EP3665181A4 (en) | Compositions and methods for decolonizing antibotic-resistant bacteria in the gut | |
EP3256495A4 (en) | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins | |
EP3474857A4 (en) | Compositions and methods for the delivery of therapeutics | |
MX2023000204A (en) | Factor h binding protein variants and methods of use thereof. | |
EP3851096A4 (en) | Liquid composition comprising protein | |
EP3488018A4 (en) | Methods and compositions for protein identification | |
DK3737402T3 (en) | Modificeret protein | |
EP3642219A4 (en) | Peptide compositions and related methods | |
IL265831A (en) | Compositions and methods for protein expression and delivery | |
IL277797A (en) | Methods for making stable protein compositions | |
EP3589315A4 (en) | Compositions and methods for inducing hiv-1 antibodies | |
IL282369A (en) | Compositions and methods for delivering transgenes | |
EP3773654C0 (en) | Polypharmaceutical drug compositions and related methods | |
EP3362048A4 (en) | Composition for intraoral delivery of biologically active peptides and proteins | |
IL291284A (en) | Systems and methods for protein expression | |
IL283229A (en) | High concentration protein formulation |